Optimal ECMO Flow in the Critical Phase of Cardiogenic Shock to Optimize Peripheral Organ Perfusion and Myocardial Stress

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Apr 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a lifesaving technique called veno-arterial ECMO (VA ECMO) in patients experiencing a severe condition known as cardiogenic shock. Cardiogenic shock happens when the heart is unable to pump enough blood to meet the body's needs, which can lead to serious complications. The trial aims to find the best way to adjust the flow of blood through the ECMO machine to ensure that organs receive enough blood while reducing stress on the heart. Researchers will monitor various health indicators over the first few days of ECMO treatment to understand how different flow rates affect both organ health and heart function.

To be eligible for this trial, participants must be adults aged 65 to 74 who are experiencing cardiogenic shock and have been receiving VA ECMO for less than 48 hours. Certain conditions, such as having just had heart surgery or being in a state of septic shock, will exclude individuals from participating. Throughout the trial, participants can expect to have their heart and organ function carefully monitored through various tests and measurements, which will help doctors learn how to improve care for future patients in similar situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • cardiogenic shock
• • treated with VA ECMO for less than 48hours
• Exclusion Criteria:
• • ECMO initiated for refractory cardiac arrest
• • Cardiac arres prior to the cardiogenic shock with Low-Flow \> 30 min
• • Noradrenaline dose \> 1μg/kg/min, vasopressin dose \> 2IU/h, dobutamine dose \> 15μg/kg/min, adrenaline dose \> 1μg/kg/min, or unstabilized vasopressors or inotropes
• • Post-cardiotomy cardiogenic shock
• • Septic shock
• • Left ventricular unloading by Impella (CP/5) or atrioseptostomy
• • Atrial septal defect
• • Ventricular septal defect
• • Pregnant or breast-feeding women
• • Patients protected by law (under guardianship or curatorship),
• • Patient participating in another research study with an exclusion period still in progress
• • Opposition to participation after having been informed
• • Patient not affiliated to any health care system
• • Patient unable to express non-opposition without available trusted person